Fragile X-associated tremor/ataxia syndrome

Handbook of Clinical Neurology

Volumn 103, Issue , 2012, Pages 373-386

  Leehey, Maureen A ^a   Hagerman, Paul J ^b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79961135207     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-444-51892-7.00023-1     Document Type: Chapter

References (130)

1. Adams J.S., Adams P.E., Nguyen D., et al. Volumetric brain changes in females with fragile X-associated tremor/ataxia syndrome (FXTAS). Neurology 2007, 69:851-859.
2. Al-Hinti J.T., Nagan N., Harik S.I. Fragile X premutation in a woman with cognitive impairment, tremor, and history of premature ovarian failure. Alzheimer Dis Assoc Disord 2007, 21:262-264.
3. Allen E.G., Juncos J., Letz R., et al. Detection of early FXTAS motor symptoms using the CATSYS computerised neuromotor test battery. J Med Genet 2008, 45:290-297.
4. Allingham-Hawkins D.J., Babul-Hirji R., Chitayat D., et al. Fragile X premutation is a significant risk factor for premature ovarian failure: the International Collaborative POF in Fragile X study - preliminary data. Am J Med Genet 1999, 83:322-325.
5. Annegers J.F., Appel S., Lee J.R., et al. Incidence and prevalence of amyotrophic lateral sclerosis in Harris County, Texas, 1985-1988. Arch Neurol 1991, 48:589-593.
6. Arocena D.G., Iwahashi C.K., Won N., et al. Induction of inclusion formation and disruption of lamin A/C structure by premutation CGG-repeat RNA in human cultured neural cells. Human Mol Genet 2005, 14:3661-3671.
7. Bacalman S., Farzin F., Bourgeois J.A., et al. Psychiatric phenotype of the fragile X-associated tremor/ataxia syndrome (FXTAS) in males: newly described fronto-subcortical dementia. J Clin Psychiatry 2006, 67:87-94.
8. Berman R.F., Willemsen R. Mouse models of fragile x-associated tremor ataxia. J Investig Med 2009, 57:837-841.
9. Berry-Kravis E., Lewin F., Wuu J., et al. Tremor and ataxia in fragile X premutation carriers: blinded videotape study. Ann Neurol 2003, 53:616-623.
10. Berry-Kravis E., Potanos K., Weinberg D., et al. Fragile X-associated tremor/ataxia syndrome in sisters related to X-inactivation. Ann Neurol 2005, 57:144-147.
11. Berry-Kravis E., Goetz C.G., Leehey M.A., et al. Neuropathic features in fragile X premutation carriers. Am J Med Genet A 2007, 143:19-26.
12. Berry-Kravis E., Abrams L., Coffey S.M., et al. Fragile X-associated tremor/ataxia syndrome: clinical features, genetics, and testing guidelines. Mov Disord 2007, 22:2018-2030.
13. Biancalana V., Toft M., Le Ber I., et al. FMR1 premutations associated with fragile X-associated tremor/ataxia syndrome in multiple system atrophy. Arch Neurol 2005, 62:962-966.
14. Botez M.I., Botez-Marquard T., Elie R., et al. Amantadine hydrochloride treatment in heredodegenerative ataxias: a double blind study. J Neurol Neurosurg Psychiatry 1996, 61:259-264.
15. Bourgeois J.A., Cogswell J.B., Hessl D., et al. Cognitive, anxiety and mood disorders in the fragile X-associated tremor/ataxia syndrome. Gen Hosp Psychiatry 2007, 29:349-356.
16. Brega A.G., Goodrich G., Bennett R.E., et al. The primary cognitive deficit among males with fragile X-associated tremor/ataxia syndrome (FXTAS) is a dysexecutive syndrome. J Clin Exp Neuropsychol 2008, 30:853-869.
17. Brouwer J.R., Huizer K., Severijnen L.A., et al. CGG-repeat length and neuropathological and molecular correlates in a mouse model for fragile X-associated tremor/ataxia syndrome. J Neurochem 2008, 107:1671-1682.
18. Brouwer J.R., Severijnen E., de Jong F.H., et al. Altered hypothalamus-pituitary-adrenal gland axis regulation in the expanded CGG-repeat mouse model for fragile X-associated tremor/ataxia syndrome. Psychoneuroendocrinology 2008, 33:863-873.
19. Brouwer J.R., Willemsen R., Oostra B.A. The FMR1 gene and fragile X-associated tremor/ataxia syndrome. Am J Med Genet B Neuropsychiatr Genet 2009, 150B:782-798.
20. Brunberg J.A., Jacquemont S., Hagerman R.J., et al. Fragile X premutation carriers: characteristic MR imaging findings of adult male patients with progressive cerebellar and cognitive dysfunction. AJNR Am J Neuroradiol 2002, 23:1757-1766.
21. Brussino A., Gellera C., Saluto A., et al. FMR1 gene premutation is a frequent genetic cause of late-onset sporadic cerebellar ataxia. Neurology 2005, 64:145-147.
22. Chancellor A.M., Warlow C.P. Adult onset motor neuron disease: worldwide mortality, incidence and distribution since 1950. J Neurol Neurosurg Psychiatry 1992, 55:1106-1115.
23. Coffey S.M., Cook K., Tartaglia N., et al. Expanded clinical phenotype of women with the FMR1 premutation. Am J Med Genet A 2008, 146A:1009-1016.
24. Cohen S., Masyn K., Adams J., et al. Molecular and imaging correlates of the fragile X-associated tremor/ataxia syndrome. Neurology 2006, 67:1426-1431.
25. Crawford D.C., Meadows K.L., Newman J.L., et al. Prevalence of the fragile X syndrome in African-Americans. Am J Med Genet 2002, 110:226-233.
26. Deng H., Le W., Jankovic J. Premutation alleles associated with Parkinson disease and essential tremor. JAMA 2004, 292:1685-1686.
27. de Rijk M.C., Breteler M.M., Graveland G.A., et al. Prevalence of Parkinson's disease in the elderly: the Rotterdam Study. Neurology 1995, 45:2143-2146.
28. de Rijk M.C., Tzourio C., Breteler M.M., et al. Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson's disease. J Neurol Neurosurg Psychiatry 1997, 62:10-15.
29. Dombrowski C., Levesque S., Morel M.L., et al. Premutation and intermediate-size FMR1 alleles in 10572 males from the general population: loss of an AGG interruption is a late event in the generation of fragile X syndrome alleles. Hum Mol Genet 2002, 11:371-378.
30. Dorn M.B., Mazzocco M.M., Hagerman R.J. Behavioral and psychiatric disorders in adult male carriers of fragile X. J Am Acad Child Adolesc Psychiatry 1994, 33:256-264.
31. Ferrara J.M., Adam O.R., Ondo W.G. Treatment of fragile-X-associated tremor/ataxia syndrome with deep brain stimulation. Mov Disord 2009, 24:149-151.
32. Finsterer J. Myotonic dystrophy type 2. Eur J Neurol 2002, 9:441-447.
33. Franke P., Leboyer M., Gansicke M., et al. Genotype-phenotype relationship in female carriers of the premutation and full mutation of FMR-1. Psychiatry Res 1998, 80:113-127.
34. Fu Y.H., Kuhl D.P., Pizzuti A., et al. Variation of the CGG repeat at the fragile X site results in genetic instability: resolution of the Sherman paradox. Cell 1991, 67:1047-1058.
35. Garcia-Arocena D., Hagerman P.J. Advances in understanding the molecular basis of FXTAS. Human molecular genetics. Hum Mol Genet 2010, 19:R83-R89.
36. Garcia-Arocena D., Yang J.E., Brouwer J.R., et al. Fibroblast phenotype in male carriers of FMR1 premutation alleles. Hum Mol Genet 2010, 19:299-312.
37. Garland E.M., Vnencak-Jones C.L., Biaggioni I., et al. Fragile X gene premutation in multiple system atrophy. J Neurol Sci 2004, 227:115-118.
38. Gilman S., Low P.A., Quinn N., et al. Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci 1999, 163:94-98.
39. Gokden M., Al-Hinti J.T., Harik S.I. Peripheral nervous system pathology in fragile X tremor/ataxia syndrome (FXTAS). Neuropathology 2008, 29:280-284.
40. Greco C.M., Hagerman R.J., Tassone F., et al. Neuronal intranuclear inclusions in a new cerebellar tremor/ataxia syndrome among fragile X carriers. Brain 2002, 125:1760-1771.
41. Greco C.M., Berman R.F., Martin R.M., et al. Neuropathology of fragile X-associated tremor/ataxia syndrome (FXTAS). Brain 2006, 129:243-255.
42. Greco C.M., Soontrapornchai K., Wirojanan J., et al. Testicular and pituitary inclusion formation in fragile X associated tremor/ataxia syndrome. J Urol 2007, 177:1434-1437.
43. Greco C.M., Tassone F., Garcia-Arocena D., et al. Clinical and neuropathologic findings in a woman with the FMR1 premutation and multiple sclerosis. Arch Neurol 2008, 65:1114-1116.
44. Grigsby J., Brega A.G., Jacquemont S., et al. Impairment in the cognitive functioning of men with fragile X-associated tremor/ataxia syndrome (FXTAS). J Neurol Sci 2006, 248:227-233.
45. Grigsby J., Brega A.G., Engle K., et al. Cognitive profile of fragile X premutation carriers with and without fragile X-associated tremor/ataxia syndrome. Neuropsychology 2008, 22:48-60.
46. Hagerman P.J. The fragile X prevalence paradox. J Med Genet 2008, 45:498-499.
47. Hagerman P.J., Hagerman R.J. The fragile-X premutation: a maturing perspective. Am J Hum Genet 2004, 74:805-816.
48. Hagerman R.J., Leehey M., Heinrichs W., et al. Intention tremor, parkinsonism, and generalized brain atrophy in male carriers of fragile X. Neurology 2001, 57:127-130.
49. Hagerman R.J., Leavitt B.R., Farzin F., et al. Fragile-X-associated tremor/ataxia syndrome (FXTAS) in females with the FMR1 premutation. Am J Hum Genet 2004, 74:1051-1056.
50. Hagerman R.J., Coffey S.M., Maselli R., et al. Neuropathy as a presenting feature in fragile X-associated tremor/ataxia syndrome. Am J Med Genet A 2007, 143A:2256-2260.
51. Hagerman R.J., Hall D.A., Coffey S., et al. Treatment of fragile X-associated tremor ataxia syndrome (FXTAS) and related neurological problems. Clin Interv Aging 2008, 3:251-262.
52. Hall D.A., Berry-Kravis E., Jacquemont S., et al. Initial diagnoses given to persons with the fragile X associated tremor/ataxia syndrome (FXTAS). Neurology 2005, 65:299-301.
53. Hall D.A., Hagerman R.J., Hagerman P.J., et al. Prevalence of FMR1 repeat expansions in movement disorders. A systematic review. Neuroepidemiology 2006, 26:151-155.
54. Hall D.A., Berry-Kravis E., Hagerman R.J., et al. Symptomatic treatment in the fragile X-associated tremor/ataxia syndrome. Mov Disord 2006, 21:1741-1744.
55. Hessl D., Tassone F., Loesch D.Z., et al. Abnormal elevation of FMR1 mrna is associated with psychological symptoms in individuals with the fragile X premutation. Am J Med Genet B Neuropsychiatr Genet 2005, 139:115-121.
56. Huntington Study Group Unified Huntington's Disease Rating Scale: reliability and consistency. Mov Disord 1996, 11:136-142.
57. Iwahashi C.K., Yasui D.H., An H.J., et al. Protein composition of the intranuclear inclusions of FXTAS. Brain 2006, 129:256-271.
58. Jacquemont S., Hagerman R.J., Leehey M., et al. Fragile X premutation tremor/ataxia syndrome: molecular, clinical, and neuroimaging correlates. Am J Hum Genet 2003, 72:869-878.
59. Jacquemont S., Hagerman R.J., Leehey M.A., et al. Penetrance of the fragile X-associated tremor/ataxia syndrome in a premutation carrier population. JAMA 2004, 291:460-469.
60. Jacquemont S., Farzin F., Hall D., et al. Aging in individuals with the FMR1 mutation. Am J Ment Retard 2004, 109:154-164.
61. Jacquemont S., Orrico A., Galli L., et al. Spastic paraparesis, cerebellar ataxia, and intention tremor: a severe variant of FXTAS?. J Med Genet 2005, 42:e14.
62. Jacquemont S., Leehey M.A., Hagerman R.J., et al. Size bias of fragile X premutation alleles in late-onset movement disorders. J Med Genet 2006, 43:804-809.
63. Jacquemont S., Hagerman R.J., Hagerman P.J., et al. Fragile-X syndrome and fragile X-associated tremor/ataxia syndrome: two faces of FMR1. Lancet Neurol 2007, 6:45-55.
64. Jankovic J., Ondo W.G., Stacy M.A., et al. A multicenter, double-blind, placebo controlled trial of topiramate in essential tremor. Mov Disord 2004, 19:S448-S449.
65. Jin P., Duan R., Qurashi A., et al. Pur alpha binds to rcgg repeats and modulates repeat-mediated neurodegeneration in a Drosophila model of fragile X tremor/ataxia syndrome. Neuron 2007, 55:556-564.
66. Kamm C., Healy D.G., Quinn N.P., et al. The fragile X tremor ataxia syndrome in the differential diagnosis of multiple system atrophy: data from the EMSA Study Group. Brain 2005, 128:1855-1860.
67. Karmon Y., Gadoth N. Fragile X associated tremor/ataxia syndrome (FXTAS) with dementia in a female harbouring FMR1 premutation. J Neurol Neurosurg Psychiatry 2008, 79:738-739.
68. Leehey M.A., Munhoz R.P., Lang A.E., et al. The fragile X premutation presenting as essential tremor. Arch Neurol 2003, 60:117-121.
69. Leehey M.A., Berry-Kravis E., Goetz C.G., et al. FMR1 CGG repeat length predicts motor dysfunction in premutation carriers. Neurology 2008, 70:1397-1402.
70. Leehey M., Hagerman R.J., Landau W.M., et al. Tremor/ataxia syndrome in fragile X carrier males. Mov Disord 2002, 17:744-745.
71. Lee J., Lacomis D., Comu S., et al. Acquired hepatocerebral degeneration: MR and pathologic findings. AJNR Am J Neuroradiol 1998, 19:485-487.
72. Loesch D.Z., Huggins R.M., Hagerman R.J. Phenotypic variation and FMRP levels in fragile X. Ment Retard Dev Disabil Res Rev 2004, 10:31-41.
73. Loesch D.Z., Churchyard A., Brotchie P., et al. Evidence for, and a spectrum of, neurological involvement in carriers of the fragile X pre-mutation: FXTAS and beyond. Clin Genet 2005, 67:412-417.
74. Loesch D.Z., Litewka L., Brotchie P., et al. Magnetic resonance imaging study in older fragile X premutation male carriers. Ann Neurol 2005, 58:326-330.
75. Louis E.D., Ottman R., Hauser W.A. How common is the most common adult movement disorder? Estimates of the prevalence of essential tremor throughout the world. Mov Disord 1998, 13:5-10.
76. Macpherson J., Waghorn A., Hammans S., et al. Observation of an excess of fragile-X premutations in a population of males referred with spinocerebellar ataxia. Hum Genet 2003, 112:619-620.
77. Mankodi A., Thornton C.A. Myotonic syndromes. Curr Opin Neurol 2002, 15:545-552.
78. Milunsky J.M., Maher T.A. Fragile X carrier screening and spinocerebellar ataxia in older males. Am J Med Genet A 2004, 125A:320.
79. Moore C.J., Daly E.M., Schmitz N., et al. A neuropsychological investigation of male premutation carriers of fragile X syndrome. Neuropsychologia 2004, 42:1934-1947.
80. Moore C.J., Daly E.M., Tassone F., et al. The effect of pre-mutation of X chromosome CGG trinucleotide repeats on brain anatomy. Brain 2004, 127:2672-2681.
81. Nelson L.M. Epidemiology of ALS. Clin Neurosci 1996, 3:327-331.
82. Oberle I., Rousseau F., Heitz D., et al. Instability of a 550-base pair DNA segment and abnormal methylation in fragile X syndrome. Science 1991, 252:1097-1102.
83. Perlman S.L. Cerebellar ataxia. Curr Treat Options Neurol 2000, 2:215-224.
84. Peters N., Kamm C., Asmus F., et al. Intrafamilial variability in fragile X-associated tremor/ataxia syndrome. Mov Disord 2006, 21:98-102.
85. Pieretti M., Zhang F.P., Fu Y.H., et al. Absence of expression of the FMR-1 gene in fragile X syndrome. Cell 1991, 66:817-822.
86. Polo J.M., Calleja J., Combarros O., et al. Hereditary ataxias and paraplegias in Cantabria, Spain. An epidemiological and clinical study. Brain 1991, 114:855-866.
87. Pugliese P., Annesi G., Cutuli N., et al. The fragile X premutation presenting as postprandial hypotension. Neurology 2004, 63:2188-2189.
88. Ranum L.P., Day J.W. Myotonic dystrophy: RNA pathogenesis comes into focus. Am J Hum Genet 2004, 74:793-804.
89. Raske C., Hagerman P.J. Molecular pathogenesis of fragile X-associated tremor/ataxia syndrome. J Investig Med 2009, 57:825-829.
90. Riddle J.E., Cheema A., Sobesky W.E., et al. Phenotypic involvement in females with the FMR1 gene mutation. Am J Ment Retard 1998, 102:590-601.
91. Ristori G., Romano S., Visconti A., et al. Riluzole in cerebellar ataxia: a randomized, double-blind, placebo-controlled pilot trial. Neurology 2010, 74:839-845.
92. Schrag A., Kingsley D., Phatouros C., et al. Clinical usefulness of magnetic resonance imaging in multiple system atrophy. J Neurol Neurosurg Psychiatry 1998, 65:65-71.
93. Schrag A., Ben-Shlomo Y., Quinn N.P. Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study. Lancet 1999, 354:1771-1775.
94. Schwartz C.E., Dean J., Howard-Peebles P.N., et al. Obstetrical and gynecological complications in fragile X carriers: a multicenter study. Am J Med Genet 1994, 51:400-402.
95. Seixas A.I., Maurer M.H., Lin M., et al. FXTAS, SCA10, and SCA17 in American patients with movement disorders. Am J Med Genet A 2005, 136:87-89.
96. Sellier C., Rau F., Liu Y., et al. Sam68 sequestration and partial loss of function are associated with splicing alterations in FXTAS patients. EMBO J 2010, 29:1248-1261.
97. Seritan A.L., Nguyen D.V., Farias S.T., et al. Dementia in fragile X-associated tremor/ataxia syndrome (FXTAS): comparison with Alzheimer's disease. Am J Med Genet B Neuropsychiatr Genet 2008, 147B:1138-1144.
98. Seritan A.L., Schneider A., Olichney J.M., et al. Conversion disorder in women with the FMR1 premutation. Am J Med Genet A 2009, 149A:2501-2506.
99. Singer C., Sanchez-Ramos J., Weiner W.J. Gait abnormality in essential tremor. Mov Disord 1994, 9:193-196.
100. Snow K., Doud L.K., Hagerman R., et al. Analysis of a CGG sequence at the FMR-1 locus in fragile X families and in the general population. Am J Hum Genet 1993, 53:1217-1228.
101. Sofola O.A., Jin P., Qin Y., et al. RNA-binding proteins hnrnp A2/B1 and CUGBP1 suppress fragile X CGG premutation repeat-induced neurodegeneration in a Drosophila model of FXTAS. Neuron 2007, 55:565-571.
102. Song F.J., Barton P., Sleightholme V., et al. Screening for fragile X syndrome: a literature review and modelling study. Health Technol Assess 2003, 7:1-106.
103. Soontarapornchai K., Maselli R., Fenton-Farrell G., et al. Abnormal nerve conduction features in fragile X premutation carriers. Arch Neurol 2008, 65:495-498.
104. Sridharan R., Radhakrishnan K., Ashok P.P., et al. Prevalence and pattern of spinocerebellar degenerations in northeastern Libya. Brain 1985, 108:831-843.
105. Storey E., Billimoria P. Increased T2 signal in the middle cerebellar peduncles on MRI is not specific for fragile X premutation syndrome. J Clin Neurosci 2005, 12:42-43.
106. Tan E.K., Zhao Y., Puong K.Y., et al. Fragile X premutation alleles in SCA, ET, and parkinsonism in an Asian cohort. Neurology 2004, 63:362-363.
107. Tassone F., Hagerman R.J., Ikle D.N., et al. FMRP expression as a potential prognostic indicator in fragile X syndrome. Am J Med Genet 1999, 84:250-261.
108. Tassone F., Hagerman R.J., Taylor A.K., et al. Elevated levels of FMR1 mrna in carrier males: a new mechanism of involvement in the fragile-X syndrome. Am J Hum Genet 2000, 66:6-15.
109. Tassone F., Hagerman R.J., Chamberlain W.D., et al. Transcription of the FMR1 gene in individuals with fragile X syndrome. Am J Med Genet 2000, 97:195-203.
110. Tassone F., Hagerman R.J., Loesch D.Z., et al. Fragile X males with unmethylated, full mutation trinucleotide repeat expansions have elevated levels of FMR1 messenger RNA. Am J Med Genet 2000, 94:232-236.
111. Tassone F., Hagerman R.J., Taylor A.K., et al. Clinical involvement and protein expression in individuals with the FMR1 premutation. Am J Med Genet 2000, 91:144-152.
112. Tassone F., Hagerman R.J., Garcia-Arocena D., et al. Intranuclear inclusions in neural cells with premutation alleles in fragile X associated tremor/ataxia syndrome. J Med Genet 2004, 41:e43.
113. Tassone F., Iwahashi C., Hagerman P.J. FMR1 RNA within the intranuclear inclusions of fragile X-associated tremor/ataxia syndrome (FXTAS). RNA Biol 2004, 1:103-105.
114. Tassone F., Adams J., Berry-Kravis E.M., et al. CGG repeat length correlates with age of onset of motor signs of the fragile X-associated tremor/ataxia syndrome (FXTAS). Am J Med Genet B Neuropsychiatr Genet 2007, 144:566-569.
115. Thompson P.J., Baxendale S.A., Duncan J.S., et al. Effects of topiramate on cognitive function. J Neurol Neurosurg Psychiatry 2000, 69:636-641.
116. Toft M., Farrer M. Premutation alleles and fragile X-associated tremor/ataxia syndrome. JAMA 2005, 293:296. author reply 96-97.
117. Togasaki D.M., Tanner C.M. Epidemiologic aspects. Adv Neurol 2000, 82:53-59.
118. Traynor B.J., Codd M.B., Forde C., et al. Incidence and prevalence of ALS in Ireland, 1995-1997: a population-based study. Neurology 1999, 52:504-509.
119. Turner G., Webb T., Wake S., et al. Prevalence of fragile X syndrome. Am J Med Genet 1996, 64:196-197.
120. Vanacore N. Epidemiological evidence on multiple system atrophy. J Neural Transm 2005, 112:1605-1612.
121. Van Den Eeden S.K., Tanner C.M., Bernstein A.L., et al. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am J Epidemiol 2003, 157:1015-1022.
122. van de Warrenburg B.P., Sinke R.J., Verschuuren-Bemelmans C.C., et al. Spinocerebellar ataxias in the Netherlands: prevalence and age at onset variance analysis. Neurology 2002, 58:702-708.
123. Van Esch H., Dom R., Bex D., et al. Screening for FMR-1 premutations in 122 older Flemish males presenting with ataxia. Eur J Hum Genet 2005, 13:121-123.
124. Verkerk A.J., Pieretti M., Sutcliffe J.S., et al. Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell 1991, 65:905-914.
125. Wasielewski P.G., Burns J.M., Koller W.C. Pharmacologic treatment of tremor. Mov Disord 1998, 13:90-100.
126. Wenzel H.J., Hunsaker M.R., Greco C.M., et al. Ubiquitin-positive intranuclear inclusions in neuronal and glial cells in a mouse model of the fragile X premutation. Brain Res 2010, 1318:155-166.
127. Yu S., Pritchard M., Kremer E., et al. Fragile X genotype characterized by an unstable region of DNA. Science 1991, 252:1179-1181.
128. Zesiewicz T.A., Sullivan K.L., Freeman A., et al. Treatment of imbalance with varenicline Chantix(R): report of a patient with fragile X tremor/ataxia syndrome. Acta Neurol Scand 2009, 119:135-138.
129. Zesiewicz T.A., Sullivan K.L., Gooch C.L., et al. Subjective improvement in proprioception in 2 patients with atypical Friedreich ataxia treated with varenicline (Chantix). J Clin Neuromuscul Dis 2009, 10:191-193.
130. Zuhlke C., Budnik A., Gehlken U., et al. FMR1 premutation as a rare cause of late onset ataxia - evidence for FXTAS in female carriers. J Neurol 2004, 251:1418-1419.